CCC. Contreras-Meca

C. Contreras-Meca

*This is an algorithmically generated author record based on publicly available information.

C. Contreras-Meca has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands

    by L. Maas, C. Contreras-Meca, S. Ghezzo, F. Belmans, A. Corsi, J. Cant, W. Vos, M. Bobowicz, M. Rygusik, P. T. Wysocki, et al.

    Given the potential of artificial intelligence (AI) and the increasing importance of understanding AI's economic impact, this study aims to provide insights into the potential cost-effectiveness of an AI tool in the response prediction to neoadjuvant chemoradiotherapy (nCRT) of Stage II-III LARC patients in comparison to usual care (UC). This study included a state-transition Markov model from a Dutch societal perspective. Quality-adjusted life years (QALY) and costs were simulated over a 10-year horizon. Sensitivity analyses and a threshold analysis were performed. Results were presented as incremental cost-effectiveness ratios. With incremental cost savings of -€2,530,000 per QALY gained per 1000 patients, the AI is dominant in the base-case. Main drivers of cost-effectiveness were the clinical complete response incidence and specificity of the tool. Cost-effectiveness was maintained at a cost of €1,100 and €2,100 for an AI performance of 0.85 and 0.90. Findings of this study present the economic impact of a hypothetical AI-based approach to treatment response prediction in Stage II-III LARC patients who receive nCRT and are eligible for consecutive surgery. The results of this study highlight the complexity of healthcare decision-making in tools that could be cost-saving yet yield lower effectiveness when parameters are uncertain.


  • Open Access

    Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy

    by L. Maas, C. Contreras-Meca, S. Ghezzo, F. Belmans, A. Corsi, J. Cant, W. Vos, M. Rygusik, D. K. Laski, L. Annemans, et al.

    Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related death. Cirrhosis is a major contributing factor, accounting for over 90% of HCC cases. With the high mortality rate of HCC, earlier detection of HCC is critical. When added to magnetic resonance imaging (MRI), artificial intelligence (AI) has been shown to improve HCC detection. Nonetheless, to date no cost-effectiveness analyses have been conducted on an AI tool to enhance earlier HCC detection. This study reports on the cost-effectiveness of detection of liver lesions with AI improved MRI in the surveillance for HCC in patients with a cirrhotic liver compared to usual care (UC). The model structure included a decision tree followed by a state-transition Markov model from an Italian healthcare perspective. Lifetime costs and quality-adjusted life years (QALY) were simulated in cirrhotic patients at risk of HCC. One-way sensitivity analyses and two-way sensitivity analyses were performed. Results were presented as incremental cost-effectiveness ratios (ICER). For patients receiving UC, the average lifetime costs per 1,000 patients were €16,604,800 compared to €16,610,250 for patients receiving the AI approach. With a QALY gained of 0.55 and incremental costs of €5,000 for every 1,000 patients, the ICER was €9,888 per QALY gained, indicating cost-effectiveness with the willingness-to-pay threshold of €33,000/QALY gained. Main drivers of cost-effectiveness included the cost and performance (sensitivity and specificity) of the AI tool. This study suggests that an AI-based approach to earlier detect HCC in cirrhotic patients can be cost-effective. By incorporating cost-effective AI-based approaches in clinical practice, patient outcomes and healthcare efficiency are improved.